Payment overview · 2025
General Payments
$951.69
49 reported records · 18 companies
Healthcare provider profile · identity verified
Danielle Marie Fuselier
Allopathic & Osteopathic Physicians|Family Medicine · CROWLEY, LA · NPI 1376997841
Verified facts
What the public records show
CMS Open Payments records show Danielle Marie Fuselier received $951.69 in general payments during 2025 across 49 reported records.
ABBVIE INC. accounted for 19.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 29 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro, Nexletol, Ozempic, Shingrix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Farxiga by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLETOL as an associated drug or biological on 24230 records involving 12642 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Nexletol by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $181.32 | 19.1% | 11 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $158.97 | 16.7% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $147.42 | 15.5% | 7 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $62.84 | 6.6% | 3 | 2025 |
| MIMEDX Group, Inc. | Unresolved — no canonical attribution shown | $44.47 | 4.7% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $43.88 | 4.6% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $41.99 | 4.4% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $38.33 | 4.0% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $33.85 | 3.6% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $33.49 | 3.5% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $31.48 | 3.3% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $27.76 | 2.9% | 1 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $21.43 | 2.2% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $18.37 | 1.9% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $18.12 | 1.9% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $17.87 | 1.9% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $15.45 | 1.6% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.65 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $951.69 | 49 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $158.97 | 6 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $97.29 | 6 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $97.29 | 6 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $95.44 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $65.51 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $62.84 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $60.11 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $51.98 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $40.81 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $38.33 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $38.33 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $33.85 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $30.30 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $30.30 | 2 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $27.76 | 1 | 2025 |
Source payment records
|
|||||
| COLLAGENASE SANTYL Normalized: collagenase santyl |
Drug | Smith+Nephew, Inc. | $21.43 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $19.26 | 1 | 2025 |
Source payment records
|
|||||
| AVYCAZ Normalized: avycaz |
Drug | ABBVIE INC. | $18.52 | 1 | 2025 |
Source payment records
|
|||||
| DALVANCE Normalized: dalvance |
Drug | ABBVIE INC. | $18.52 | 1 | 2025 |
Source payment records
|
|||||
| TEFLARO Normalized: teflaro |
Drug | ABBVIE INC. | $18.52 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $18.37 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $18.37 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $17.87 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $16.29 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.45 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $15.19 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $14.65 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.23 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $13.58 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 47 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 118 | exact normalized | Medicare Part D |
| NEXLETOL nexletol |
2025 | Nexletol | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 79 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 23 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
59 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLETOL open payments reported associated product |
CMS Open Payments — General Payments 24230 supporting records · 12642 recipient NPIs · example record 1243949989 |
Nexletol · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
23 | 16 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
81 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
118 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
79 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 518 | 122 |
| Levothyroxine Sodium | Levothyroxine Sodium | 472 | 83 |
| Lisinopril | Lisinopril | 308 | 72 |
| Gabapentin | Gabapentin | 264 | 68 |
| Metformin Hcl | Metformin Hcl | 256 | 62 |
| Pantoprazole Sodium | Pantoprazole Sodium | 237 | 69 |
| Fluticasone Propionate | Fluticasone Propionate | 222 | 79 |
| Omeprazole | Omeprazole | 195 | 48 |
| Furosemide | Furosemide | 186 | 44 |
| Hydrochlorothiazide | Hydrochlorothiazide | 184 | 44 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 181 | 48 |
| Amlodipine Besylate | Amlodipine Besylate | 179 | 46 |
| Trazodone Hcl | Trazodone Hcl | 163 | 46 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 154 | 55 |
| Buspirone Hcl | Buspirone Hcl | 135 | 32 |
| Fluoxetine Hcl | Fluoxetine Hcl | 134 | 35 |
| Quetiapine Fumarate | Quetiapine Fumarate | 131 | 23 |
| Simvastatin | Simvastatin | 126 | 15 |
| Prednisone | Prednisone | 125 | 90 |
| Mounjaro | Tirzepatide | 118 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 114 | 24 |
| Ezetimibe | Ezetimibe | 112 | 35 |
| Metoprolol Succinate | Metoprolol Succinate | 106 | 29 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 103 | 27 |
| Citalopram Hbr | Citalopram Hydrobromide | 101 | 16 |
| Tamsulosin Hcl | Tamsulosin Hcl | 98 | 25 |
| Losartan Potassium | Losartan Potassium | 96 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 93 | 20 |
| Meloxicam | Meloxicam | 93 | 28 |
| Mirtazapine | Mirtazapine | 90 | 17 |
| Pregabalin | Pregabalin | 90 | 22 |
| Azithromycin | Azithromycin | 87 | 64 |
| Montelukast Sodium | Montelukast Sodium | 83 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 83 | 19 |
| Tramadol Hcl | Tramadol Hcl | 81 | 39 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 81 | 12 |
| Ozempic | Semaglutide | 79 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 79 | 21 |
| Sertraline Hcl | Sertraline Hcl | 78 | 16 |
| Sucralfate | Sucralfate | 76 | 20 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 72 | 23 |
| Glipizide | Glipizide | 71 | 23 |
| Clonazepam | Clonazepam | 69 | suppressed |
| Carvedilol | Carvedilol | 64 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 64 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 64 | 12 |
| Famotidine | Famotidine | 63 | 15 |
| Metformin Hcl Er | Metformin Hcl | 61 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 61 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 61 | 20 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 60 | 46 |
| Potassium Chloride | Potassium Chloride | 60 | 11 |
| Linzess | Linaclotide | 59 | suppressed |
| Risperidone | Risperidone | 59 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 58 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 56 | 18 |
| Repatha Syringe | Evolocumab | 56 | suppressed |
| Aripiprazole | Aripiprazole | 55 | suppressed |
| Glimepiride | Glimepiride | 54 | 13 |
| Donepezil Hcl | Donepezil Hcl | 52 | 14 |
| Alendronate Sodium | Alendronate Sodium | 51 | suppressed |
| Amoxicillin | Amoxicillin | 51 | 44 |
| Finasteride | Finasteride | 51 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 51 | 35 |
| Mupirocin | Mupirocin | 50 | 32 |
| Amitriptyline Hcl | Amitriptyline Hcl | 49 | 19 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 48 | 44 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 47 | 24 |
| Eliquis | Apixaban | 47 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 47 | 15 |
| Atenolol | Atenolol | 42 | suppressed |
| Lorazepam | Lorazepam | 42 | suppressed |
| Spironolactone | Spironolactone | 41 | 14 |
| Alprazolam | Alprazolam | 39 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 39 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 39 | suppressed |
| Memantine Hcl | Memantine Hcl | 38 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 38 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 37 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 36 | suppressed |
| Glipizide Er | Glipizide | 36 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 35 | 13 |
| Allopurinol | Allopurinol | 34 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 34 | suppressed |
| Ibuprofen | Ibuprofen | 34 | 17 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 34 | suppressed |
| Diazepam | Diazepam | 33 | 11 |
| Lovastatin | Lovastatin | 33 | suppressed |
| Vascepa | Icosapent Ethyl | 33 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 32 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 31 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 30 | 25 |
| Bupropion Hcl Sr | Bupropion Hcl | 29 | suppressed |
| Jardiance | Empagliflozin | 29 | suppressed |
| Lamotrigine | Lamotrigine | 29 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 29 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 28 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 28 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 28 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 28 | 15 |
| Ibu | Ibuprofen | 27 | suppressed |
| Levetiracetam | Levetiracetam | 26 | suppressed |
| Naproxen | Naproxen | 26 | 11 |
| Raloxifene Hcl | Raloxifene Hcl | 26 | suppressed |
| Entresto | Sacubitril/Valsartan | 25 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 25 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 25 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 25 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 24 | 17 |
| Lactulose | Lactulose | 24 | suppressed |
| Celecoxib | Celecoxib | 23 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 23 | 13 |
| Methylprednisolone | Methylprednisolone | 23 | 22 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 23 | 16 |
| Clindamycin Hcl | Clindamycin Hcl | 22 | 16 |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | 13 |
| Repatha Sureclick | Evolocumab | 21 | suppressed |
| Temazepam | Temazepam | 21 | suppressed |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 20 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 20 | 18 |
| Methocarbamol | Methocarbamol | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 19 |
| Testosterone Cypionate | Testosterone Cypionate | 20 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Fluconazole | Fluconazole | 19 | 13 |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 19 | 15 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Ramipril | Ramipril | 19 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 18 | suppressed |
| Estradiol | Estradiol | 17 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 17 | suppressed |
| Praluent Pen | Alirocumab | 17 | suppressed |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 16 | suppressed |
| Levofloxacin | Levofloxacin | 16 | 14 |
| Megestrol Acetate | Megestrol Acetate | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | 14 |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 14 | suppressed |
| Olanzapine | Olanzapine | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Cephalexin | Cephalexin | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Phenytoin | Phenytoin | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Cilostazol | Cilostazol | 11 | suppressed |
| Haloperidol | Haloperidol | 11 | suppressed |
| Kerendia | Finerenone | 11 | suppressed |
| Nexletol | Bempedoic Acid | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $951.69 · 49 records | ABBVIE INC. | AREXVY, AVYCAZ, CAPLYTA, COLLAGENASE SANTYL, Cologuard Collection Kit, DALVANCE, ELIQUIS, EVENITY, FARXIGA, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, IBSRELA, JARDIANCE, MOUNJARO, NEXLETOL, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, SHINGRIX, TEFLARO, UBRELVY, VRAYLAR, WATCHMAN Access System, Wegovy, XIFAXAN, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error